Today, the European Medicines Agency (EMEA) issued an announcement recommending the suspension of marketing authorization for Acomplia (rimonabant) jusacross the entire European Union. The Agency’s Committee for Medicinal Products for Human Use completed its review of the evidence on the drug’s effectiveness and safety, specifically psychiatric adverse reactions, at the request of the European
